9/22/2025

Pfizer Inc. acquires Metsera, Inc. for up to $7.5B, boosting its obesity pipeline with new therapies. Click for potential FDA action and the impact on PFE and MTSR.

Source: SeekingAlpha

9/22/2025

Pfizer Inc. acquires Metsera, Inc. to re-enter the obesity drug market. Click for my look at PFZ and MTSR stock and where I see value in the weight loss sector.

Source: SeekingAlpha

9/21/2025

With a weight-loss pill on the horizon and the FDA’s signal of a tougher stance on compounded knockoffs, Novo Nordisk might be turning a corner.

Source: Yahoo

9/21/2025

Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in Goochland County, Virginia. This is the first of four new U.S. production locations that Eli Lilly & Company (NYSE:LLY) hopes to reveal […]

Source: Yahoo

9/21/2025

Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.

Source: SeekingAlpha

9/20/2025

These two underperforming stocks remain attractive for long-term dividend-seeking investors.

Source: Yahoo

9/20/2025

JPMorgan Chase & Co. (NYSE:JPM) is one of the stocks stocks Jim Cramer recently discussed. Cramer said that it could be the next trillion-dollar stock. He stated: “The anomaly this time, it looks like the next trillion-dollar stock won’t be Eli Lilly. If anything, it’s more likely to be the stock of JPMorgan, a bank… […]

Source: Yahoo

9/20/2025

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. While talking about the company, Cramer said that investors are not “supposed to buy drug stocks” when the Fed is cutting rates. He remarked: “Not that long ago, pretty much everybody assumed that the next non-tech stock to cross the trillion-dollar […]

Source: Yahoo

9/19/2025

The initiative is part of Trump’s demands that drugmakers reduce their prices to align them with what other developed countries pay, according to the people, who spoke on condition of anonymity to discuss plans that are not yet public. The proposed website would allow patients to search for specific medicines and be connected with platforms that sell them, the people said.

Source: Yahoo

9/19/2025

With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.

Source: Yahoo

9/19/2025

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.

Source: Yahoo

9/19/2025

Eli Lilly's initiative could make the company even more successful than it already is.

Source: Yahoo

9/19/2025

With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.

Source: Yahoo

9/19/2025

Novo Nordisk A/S's outlook downgrades are concerning, but strong growth potential and positive study results make NVO stock worth considering. Learn more about NVO stock here.

Source: SeekingAlpha

9/19/2025

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.

Source: Yahoo

9/19/2025

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Source: Yahoo

9/19/2025

Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.

Source: Yahoo

9/18/2025

VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly. The team, known internally as cardiometabolic educators, sat within Novo Nordisk's commercial division and included several hundred staff, sources said.

Source: Yahoo

9/18/2025

Real-world study shows fewer heart attacks, strokes, and deaths

Source: Yahoo

9/18/2025

Eli Lilly and Co. (NYSE:LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company announced that its diabetes medication, Mounjaro, delivered positive results in Phase 3 Trials in children and adolescents with type 2 diabetes. The diabetes medication reportedly demonstrated significant improvements in blood sugar control and […]

Source: Yahoo